Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

Background: MIBC is an aggressive disease, with 5-year survival rates ranging from 36 to 48% for p T3/p T4/p N+tumors. Perioperative treatment can improve overall survival, with more robust evidence in favor of neoadjuvant chemotherapy. Few randomized studies have compared neoadjuvant and adjuvant t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Del Bene, Gabriella, Calabrò, Fabio, Giannarelli, Diana, Plimack, Elizabeth R., Harshman, Lauren C., Yu, Evan Y., Crabb, Simon J., Pal, Sumanta Kumar, Alva, Ajjai S., Powles, Thomas, De Giorgi, Ugo, Agarwal, Neeraj, Bamias, Aristotelis, Ladoire, Sylvain, Necchi, Andrea, Vaishampayan, Ulka N., Niegisch, Günter, Bellmunt, Joaquim, Baniel, Jack, Galsky, Matthew D., Sternberg, Cora N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252384/
https://ncbi.nlm.nih.gov/pubmed/30510914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00463
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky